Skip to main content

Health condition · Clinically reviewed

Ovarian cancer, the symptoms that matter and the pathway to diagnosis.

Often called a “silent” cancer because its symptoms are vague - but frequent, persistent symptoms that are new for you are the clue worth acting on.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE CG122, NICE NG12 and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance including CA125 testing, the Risk of Malignancy Index and PARP inhibitor maintenance.

Key facts

Ovarian cancer at a glance.

The essentials, in plain English - why it’s easy to miss, how it’s tested for, and how it’s treated in the UK today.

  • What it is

    A cancer arising from the ovary - most commonly epithelial ovarian cancer, which accounts for the large majority of cases.

  • Why it’s missed

    Often called a “silent” cancer - symptoms are vague and non-specific, which delays diagnosis until a later stage.

  • The real clue

    Not any single symptom, but symptoms that are frequent, persistent, and represent a change from what is normal for you.

  • Genetic risk

    BRCA1 and BRCA2 mutations significantly increase lifetime risk - genetic testing is offered to all with high-grade epithelial disease.

  • First-line test

    CA125 blood test, followed by pelvic or abdominal ultrasound if the result is suggestive.

  • Treatment backbone

    Surgery for staging and debulking, combined with platinum-based chemotherapy - and PARP inhibitors for BRCA-mutated disease.

Why this guide matters

Recognising the pattern early changes outcomes.

Ovarian cancer is treatable, especially when caught earlier. The three points below shape everything else on this page.

  • Individual symptoms are non-specific

    Bloating, appetite change and pelvic discomfort are common on their own - it’s the frequency and persistence together that matter.

  • CA125 is a first-line, not final, test

    A raised CA125 doesn’t confirm cancer, and a normal result doesn’t rule it out - it feeds into the wider Risk of Malignancy Index.

  • BRCA status changes the whole plan

    Knowing your BRCA1 or BRCA2 status affects treatment choices, including PARP inhibitor eligibility, and matters for your family too.

How the diagnosis is made

From first symptoms to a specialist plan.

The steps a UK GP and gynaecological oncology team will normally follow, in order - so you know what to expect and why, per NICE CG122 and NG12.

  1. 01

    Assessing

    Symptom recognition

    Persistent bloating, early satiety, pelvic or abdominal pain, urinary urgency and unexplained weight loss - especially when frequent and new for you.

  2. 02

    Assessing

    CA125 blood test

    The first-line investigation in primary care when symptoms are suggestive of ovarian cancer, per NICE CG122.

  3. 03

    Assessing

    Pelvic or abdominal ultrasound

    Arranged if CA125 is raised, to look at ovarian size, structure and any suspicious features.

  4. 04

    Confirming

    Risk of Malignancy Index (RMI)

    Combines the CA125 level, ultrasound findings and menopausal status into a single risk score that guides referral.

  5. 05

    Confirming

    Urgent 2-week-wait referral

    A raised RMI or strong clinical suspicion triggers urgent referral to a specialist gynaecological oncology service.

  6. 06

    Preparing

    CT staging

    CT of chest, abdomen and pelvis maps the extent of disease and informs the surgical and treatment plan.

  7. 07

    Preparing

    MDT review and BRCA testing

    A specialist gynaecological oncology multidisciplinary team plans surgery and chemotherapy; BRCA testing is offered to all with high-grade epithelial disease.

Typical timeline: a first CA125 test to an urgent specialist referral in days, not months.

Symptoms

What ovarian cancer actually feels like.

Individually vague, but together a pattern worth acting on - frequent, persistent, and a change from what is normal for you.

  • Persistent bloating

    Not the occasional bloat - bloating that is frequent, doesn’t settle, and feels different from your normal pattern.

  • Early satiety or loss of appetite

    Feeling full after only a small amount of food, or a noticeable drop in appetite that persists.

  • Pelvic or abdominal pain

    Ongoing discomfort or pain in the pelvis or abdomen that doesn’t resolve as expected.

  • Urinary urgency or frequency

    A new need to pass urine more often or more urgently, without a urinary infection to explain it.

  • Unexplained weight loss

    Weight loss without a change in diet or activity - always worth flagging to a GP.

  • Fatigue

    Persistent tiredness that isn’t explained by sleep, stress or another known cause.

  • A change from what is normal for you

    The single most important clue - these symptoms matter most when they are new, frequent and persistent, not isolated or occasional.

  • Red flag - symptoms most days for 3 weeks

    Any of the above occurring more than 12 times a month, for three weeks or more, warrants a CA125 test without delay.

Treatment

How ovarian cancer is treated in the UK.

Surgery and platinum-based chemotherapy form the backbone of treatment, with PARP inhibitors extending remission in BRCA-mutated disease.

  • Staging laparotomy

    Central to both diagnosis and treatment - confirms the extent of disease and removes as much tumour as possible.

  • Debulking surgery

    Aims to remove all visible tumour - the amount of residual disease after surgery is one of the strongest predictors of outcome.

  • Platinum-based chemotherapy

    Usually carboplatin, given alongside surgery as adjuvant or neoadjuvant treatment depending on stage and fitness.

  • Neoadjuvant chemotherapy

    Given before surgery in advanced disease to shrink tumour bulk and improve the chance of complete debulking.

  • PARP inhibitor maintenance

    Particularly effective in BRCA-mutated disease - reduces the risk of relapse after response to chemotherapy.

  • Genetic counselling and cascade testing

    Offered to all with high-grade epithelial disease, with cascade testing for family members if a BRCA mutation is found.

  • Fertility preservation discussion

    Raised early with younger patients where the stage and treatment plan may allow it.

  • Specialist MDT and palliative care

    Every case is managed by a specialist-commissioned gynaecological oncology MDT, with palliative care involved early for advanced disease.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or gynaecological oncology team knows your history and results and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Ovarian cancer: recognition and initial management (CG122).

  • NICE. Suspected cancer: recognition and referral (NG12).

  • NICE. Ovarian cancer: recognition and management guidance summary.

  • Royal College of Obstetricians and Gynaecologists (RCOG). Green-top guidelines on ovarian cancer and BRCA-related disease.

Red flags

When ovarian symptoms need urgent attention.

Most symptoms have a benign explanation. These are the situations that need prompt CA125 testing or emergency assessment.

  • Symptoms most days for 3 weeks or more

    Persistent bloating, pelvic pain, early satiety or urinary symptoms occurring frequently over three weeks or longer needs a CA125 test without delay.

  • Raised CA125 with ultrasound findings

    A raised CA125 combined with a suspicious ultrasound and an elevated RMI warrants urgent 2-week-wait referral.

  • New abdominal or pelvic mass

    A palpable mass on examination, especially in a postmenopausal woman, needs urgent specialist assessment.

  • Ascites or abdominal distension

    New fluid in the abdomen alongside other symptoms is a significant finding requiring urgent imaging and referral.

  • Family history of ovarian or breast cancer

    A strong family history, especially with known BRCA1 or BRCA2 mutations, should prompt genetic counselling and risk assessment.

  • Postmenopausal bleeding with pelvic symptoms

    Unexplained bleeding after the menopause alongside bloating or pain deserves prompt, combined gynaecological assessment.

  • Bowel obstruction symptoms

    Severe constipation, vomiting or colicky abdominal pain in advanced disease can signal bowel obstruction - an emergency needing hospital assessment.

  • Sudden severe pelvic pain

    Acute, severe pain can indicate ovarian torsion or cyst rupture - this needs same-day emergency assessment regardless of cancer risk.

  • Rapid symptom progression

    Symptoms that are worsening quickly over days to weeks, rather than developing gradually, should be reviewed urgently rather than waiting.

Living with it

From suspicion to diagnosis, and through treatment.

Four things that make the biggest difference - noticing the pattern early, asking for the right test, understanding your genetic risk, and using your specialist team fully.

A quiet reminder

Trust the pattern, not the single symptom.

No single symptom on this page confirms or rules out ovarian cancer - it’s the combination, frequency and persistence that guides your GP’s next step.

  1. 01 Notice

    Track the pattern, not the day

    Keep a simple diary of bloating, appetite, pain and urinary symptoms for a few weeks - frequency and persistence matter more than any single bad day.

  2. 02 Ask

    Ask specifically for a CA125 test

    If symptoms are new, frequent and persistent, ask your GP directly for a CA125 blood test rather than waiting to see if things settle.

  3. 03 Genetics

    Consider genetic counselling

    A family history of ovarian or breast cancer is worth discussing with your GP - genetic counselling and BRCA testing can clarify your own risk.

  4. 04 Support

    Use the specialist MDT

    Treatment and follow-up run through a specialist-commissioned gynaecological oncology team - lean on them for symptom control, fertility questions and support at every stage.

Frequently asked

Everything we get asked about ovarian cancer.

Quick answers on symptoms, CA125, BRCA testing and PARP inhibitors.

  • Why is ovarian cancer called a “silent” cancer?

    Because its early symptoms - bloating, changes in appetite, pelvic discomfort, urinary changes - are vague and easily mistaken for less serious conditions such as IBS or menopause. This often delays diagnosis until a later, less treatable stage. The key is recognising that these symptoms matter when they are frequent, persistent and different from what is normal for you.

  • What is the most common type of ovarian cancer?

    Epithelial ovarian cancer, which arises from the surface layer of the ovary, accounts for the large majority of cases. It includes several subtypes, of which high-grade serous carcinoma is the most common and the type most strongly linked to BRCA1 and BRCA2 mutations.

  • What does the CA125 blood test actually show?

    CA125 is a protein that can be raised in ovarian cancer, though it can also be elevated by conditions such as endometriosis, fibroids or pelvic infection, and is not always raised in early-stage disease. It is used as a first-line test in NICE CG122, and its result feeds into the Risk of Malignancy Index alongside ultrasound findings and menopausal status.

  • What is the Risk of Malignancy Index (RMI)?

    The RMI combines your CA125 level, ultrasound findings and menopausal status into a single score that helps clinicians decide how urgently you need specialist referral. A higher score triggers an urgent 2-week-wait referral to a gynaecological oncology service.

  • Should I be tested for BRCA1 or BRCA2?

    Genetic testing for BRCA1 and BRCA2 is offered to everyone diagnosed with high-grade epithelial ovarian cancer, regardless of family history, because the result changes both treatment options - including eligibility for PARP inhibitors - and screening advice for relatives. If you have a strong family history but no diagnosis, ask your GP about a referral for genetic counselling.

  • What are PARP inhibitors and who benefits from them?

    PARP inhibitors are oral maintenance medicines taken after a good response to chemotherapy, and they are particularly effective in BRCA-mutated ovarian cancer, where they can meaningfully extend the time before the cancer returns. Your oncology team will discuss whether you are a candidate based on your BRCA status and response to initial treatment.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.